Clinical trial
Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory…
NCT00077402 · Cancer Therapeutics Research Group, Other · Completed
Key facts
| NCT number | NCT00077402 |
|---|---|
| Title | Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer |
| Official title | A Phase 2 Study Of Fenretinide In Patients With Hormone Refractory Prostate Cancer |
| Lead sponsor | Cancer Therapeutics Research Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | fenretinide |
| Enrollment | 50 |
| Start date | Nov 1, 2003 |
| Primary completion | Jan 1, 2011 |
| Completion | Feb 1, 2011 |
| First posted | Feb 12, 2004 |
| Last update posted | May 15, 2013 |
| Countries | Australia, Hong Kong, Singapore |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: